Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Development Time Is Five Years From Target To NDA, Glaxo's Sykes Says

Executive Summary

Glaxo SmithKline's development timeline from discovery of a novel target to NDA filing would be as little as five years, Glaxo Wellcome Chairman Richard Sykes maintained during a Jan. 18 briefing on the Glaxo SmithKline merger in New York City.
Advertisement

Related Content

FTC Will Have Opportunity To Address Genomics In Review Of Glaxo/SB
FTC Will Have Opportunity To Address Genomics In Review Of Glaxo/SB
Advertisement
UsernamePublicRestriction

Register

PS035471

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel